Evasion and subversion of interferon-mediated antiviral immunity by Kaposi's sarcoma-associated herpesvirus: An Overview

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 10934-10944

  Sathish, Narayanan ^a,b   Yuan, Yan ^a  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^b INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHOPAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON REGULATORY FACTOR; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN K BZIP; PROTEIN ORF36; PROTEIN RIF; PROTEIN RTA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL IMMUNITY; CYTOKINE PRODUCTION; HUMAN; HUMAN HERPESVIRUS 8; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNITY; INNATE IMMUNITY; KAPOSI SARCOMA; LIFE CYCLE; LYSIS; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; SUBVERSION; VIRUS GENE; VIRUS LATENCY; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNE EVASION; INTERFERON TYPE I;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

EID: 80055103422     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00687-11     Document Type: Short Survey

References (143)

1. Agnello, D., et al. 2003. Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. J. Clin. Immunol. 23:147-161.
2. Ahmad, H., et al. 2011. Kaposi sarcoma-associated herpesvirus degrades cellular Toll-interleukin-1 receptor domain-containing adaptor-inducing β-interferon (TRIF). J. Biol. Chem. 286:7865-7872.
3. Akula, S. M., P. P. Naranatt, F. Z. Wang, and B. Chandran. 2001. Human herpesvirus envelope-associated glycoprotein B interacts with heparan sulfate-like moieties. Virology 284:235-249.
4. Al-khatib, K., S. R. Williams, R. H. Silverman, W. Halford, and D. J. Carr. 2003. The murine double-stranded RNA-dependent protein kinase PKR and the murine 2', 5'-oligoadenylate synthetase-dependent RNase L are required for IFN-β-mediated resistance against herpes simplex virus type I in primary trigeminal ganglion culture. Virology 313:126-135.
5. Ankel, H., D. F. Westra, S. Welling-Wester, and P. Lebon. 1998. Induction of interferon-α by glycoprotein D of herpes simplex virus: a possible role of chemokine receptors. Virology 251:317-326.
6. Aresté, C., M. Mutocheluh, and D. J. Blackbourn. 2009. Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein. J. Biol. Chem. 284:23272-23285.
7. Ballestas, M. E., P. A. Chatis, and K. M. Kaye. 1999. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284:641-644.
8. Bechtel, J. T., R. C. Winant, and D. Ganem. 2005. Host and viral proteins in the virion of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79:4952-4964.
9. Beutler, B. 2004. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430:257-263.
10. Bi, X., L. Yang, M. E. Mancl, and B. J. Barnes. 2010. Modulation of interferon regulatory factor 5 activities by the Kaposi sarcoma-associated herpesvirus-encoded viral interferon regulatory factor 3 contributes to immune evasion and lytic induction. J. Interferon Cytokine Res. 31:373-382.
11. Bisson, S. A., A. L. Page, and D. Ganem. 2009. A Kaposi's sarcomaassociated herpesvirus protein that forms inhibitory complexes with type I interferon receptor subunits, Jak and STAT proteins, and blocks interferon-mediated signal transduction. J. Virol. 83:5056-5066.
12. Boehme, K. W., J. Singh, S. T. Perry, and T. Compton. 2004. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J. Virol. 78:1202-1211.
13. Boshoff, C., and R. Weiss. 2002. AIDS-related malignancies. Nat. Rev. Cancer 2:373-382.
14. Brierley, M. M., and E. N. Fish. 2002. Review: IFN-α/β receptor interactions to biologic outcomes: understanding the circuitry. J. Interferon. Cytokine. Res. 22:835-845.
15. Brooks, J. J. 1986. Kaposi's sarcoma: a reversible hyperplasia. Lancet ii: 1309-1311.
16. Brown, H. J., et al. 2003. NF-κB inhibits gammaherpesvirus lytic replication. J. Virol. 77:8532-8540.
17. Burýsek, L., et al. 1999. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J. Virol. 73:7334-7342.
18. Burysek, L., W. S. Yeow, and P. M. Pitha. 1999. Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). J. Hum. Virol. 2:19-32.
19. Burýsek, L., and P. M. Pitha. 2001. Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNAactivated protein kinase. J. Virol. 75:2345-2352.
20. Cesarman, E., Y. Chang, P. S. Moore, J. W. Said, and D. M. Knowles. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDSrelated body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191.
21. Cesarman, E., et al. 1995. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-l and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86:2708-2714.
22. Cesarman, E., E. A. Mesri, and M. C. Gershengorn. 2000. Viral G proteincoupled receptor and Kaposi's sarcoma: a model of paracrine neoplasia? J. Exp. Med. 191:417-422.
23. Chandran, B. 2010. Early events in Kaposi's sarcoma-associated herpesvirus infection of target cells. J. Virol. 84:2188-2199.
24. Chang, Y., et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266:1865-1869.
25. Cloutier, N., A. Gravel, and L. Flamand. 2004. Multiplex detection and quantitation of latent and lytic transcripts of human herpesvirus-8 using RNase protection assay. J. Virol. Methods 122:1-7.
26. Cloutier, N., and L. Flamand. 2010. Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) β expression by competing with IFN regulatory factor-3 for binding to IFNB promoter. J. Biol. Chem. 285:7208-7221.
27. Coscoy, L., and D. D. Ganem. 2000. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl. Acad. Sci. U. S. A. 97:8051-8056.
28. Coscoy, L., and D. D. Ganem. 2001. A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J. Clin. Invest. 107:1599-1606.
29. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
30. Dezube, B. J. 1996. Clinical presentation and natural history of AIDSrelated Kaposi's sarcoma. Hematol. Oncol. Clin. North Am. 10:1023-1029.
31. Duguay, D., et al. 2002. In vivo interferon regulatory factor 3 tumor suppressor activity in B16 melanoma tumors. Cancer Res. 62:5148-5152.
32. Erlandsson, L., et al. 1998. Interferon-β is required for interferon-α production in mouse fibroblasts. Curr. Biol. 8:223-226.
33. Fakhari, F. D., and D. P. Dittmer. 2002. Charting latency transcripts in Kaposi's sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J. Virol. 76:6213-6223.
34. Fitzgerald, K. A., et al. 2003. IKK∑?and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4:491-496.
35. Fitzgerald, K. A., et al. 2003. LPS-TLR4 signaling to IRF-3/7 and NF-κB involves the Toll adapters TRAM and TRIF. J. Exp. Med. 198:1043-1055.
36. Fuld, S., C. Cunningham, K. Klucher, A. J. Davison, and D. J. Blackbourn. 2006. Inhibition of interferon signaling by the Kaposi's sarcoma-associated herpesvirus full-length viral interferon regulatory factor 2 protein. J. Virol. 80:3092-3097.
37. Ganem, D. 2007. Kaposi's sarcoma-associated herpesvirus, p. 2875-2888. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
38. Ganem, D. 2010. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J. Clin. Invest. 120:939-949.
39. Gao, S. J., et al. 1997. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 15:1979-1985.
40. Gao, S. J., J. H. Deng, and F. C. Zhou. 2003. Productive lytic replication of a recombinant Kaposi's sarcoma-associated herpesvirus in efficient primary infection of primary human endothelial cells. J. Virol. 77:9738-9749.
41. Gershburg, E., and J. S. Pagano. 2008. Conserved herpesvirus protein kinases. Biochim. Biophys. Acta 1784:203-212.
42. Goodbourn, S., L. Didcock, and R. E. R. E. Randall. 2000. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81:2341-2364.
43. Grundhoff, A., and D. Ganem. 2004. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J. Clin. Invest. 113:124-136.
44. Häcker, H., et al. 2000. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J. Exp. Med. 192:595.
45. Hemmi, H., et al. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408:740-745.
46. Hiscott, J. 2007. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282:15325-15329.
47. Honda, K., et al. 2004. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 101:15416-15421.
48. Honda, K., et al. 2005. IRF-7 is the master regulator of type-I interferondependent immune responses. Nature 434:772-777.
49. Honda, K., Y. Hideyuki, A. Takaoka, and T. Taniguchi. 2005. Regulation of the type I IFN induction: a current view. Int. Immunol. 17:1367-1378.
50. Honda, K., and T. Taniguchi. 2006. IRFs: master regulators of signaling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6:644-658.
51. Hwang, S., et al. 2009. Conserved herpesviral kinase promotes viral persistence by inhibiting IRF-3-mediated type I interferon response. Cell Host Microbe 5:166-178.
52. Ishido, S., C. Wang, B. S. Lee, G. B. Cohen, and J. U. Jung. 2000. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 74:5300-5309.
53. Iwasaki, A., and R. Medzhitov. 2010. Regulation of adaptive immunity by the innate immune system. Science 327:291-295.
54. Jayachandra, S., et al. 1999. Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc. Natl. Acad. Sci. U. S. A. 96:11566-11571.
55. Jenner, R. G., M. M. Alba, C. Boshoff, and P. Kellam. 2001. Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J. Virol. 75:891-902.
56. Joo, C. H., et al. 2007. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J. Virol. 81:8282-8292.
57. Kawai, T., et al. 2001. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167:5887-5894.
58. Kawai, T., et al. 2004. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5:1061-1068.
59. Krishnan, H. H., et al. 2004. Concurrent expression of latent and a limited number of lytic genes with immune modulation and antiapoptotic function by Kaposi's sarcoma-associated herpesvirus early during infection of primary endothelial and fibroblast cells and subsequent decline of lytic gene expression. J. Virol. 78:3601-3620.
60. Lagos, D., et al. 2008. Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe 4:470-483.
61. Lagos, D., et al. 2010. miR-132 regulates antiviral innate immunity through suppression of the p300 transcriptional co-activator. Nat. Cell Biol. 12:513-519.
62. Lan, K., D. A. Kuppers, S. C. Verma, and E. S. Robertson. 2004. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virusmediated control of latency. J. Virol. 78:6585-6594.
63. Le Bon, A., et al. 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4:1009-1015.
64. Lee, H. R., M. H. Kim, J. S. Lee, C. Liang, and J. U. Jung. 2009. Viral interferon regulatory factors. J. Interferon Cytokine Res. 29:621-627.
65. Lefort, S., A. Soucy-Faulkner, N. Grandvaux, and L. Flamand. 2007. Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression. J. Virol. 81:10950-10960.
66. Levy, D. E., I. Marie, E. Smith, and A. Prakash. 2002. Enhancement and diversification of IFN induction by IRF-7-mediated positive feedback. J. Interferon Cytokine Res. 22:87-93.
67. Li, M., et al. 1998. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J. Virol. 72:5433-5440.
68. Li, M., et al. 2000. Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol. Cell. Biol. 20:8254-8263.
69. Liang, C., J. S. Lee, and J. U. Jung. 2008. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. Semin. Cancer Biol. 18:423-436.
70. Liang, D., et al. 2011. A human herpesvirus miRNA attenuates interferon signaling and contributes to maintenance of viral latency by targeting IKK∑. Cell Res. 21:793-806.
71. Lim, C., Y. Gwack, S. Hwang, S. Kim, and J. Choe. 2001. The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi's sarcomaassociated herpesvirus. J. Biol. Chem. 276:31016-31022.
72. Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott. 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. Mol. Cell. Biol. 18:2986-2996.
73. Lin, R., Y. Mamane, and J. Hiscott. 1999. Structural and functional analysis of interferon regulatory factor 3: localization of the transactivation and autoinhibitory domains. Mol. Cell. Biol. 19:2465.
74. Lin, R., Y. Mamane, and J. Hiscott. 2000. Multiple regulatory domains control IRF-7 activity in response to virus infection. J. Biol. Chem. 275: 34320-34327.
75. Lin, R. P., et al. 2001. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene 20:800-811.
76. Lin, S. F., D. R. Robinson, G. Miller, and H. J. Kung. 1999. Kaposi's sarcoma-associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein-Barr virus. J. Virol. 73:1909-1917.
77. Lord, K. A., B. Hoffman-Liebermann, and D. A. Liebermann. 1990. Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6. Oncogene 5:1095-1097.
78. Lubyova, B., and P. M. Pitha. 2000. Characterization of a novel human herpesvirus 8-encoded protein, vIRF-3, that shows homology to viral and cellular interferon regulatory factors. J. Virol. 74:8194-8201.
79. Lubyova, B., M. J. Kellum, A. J. Frisancho, and P. M. Pitha. 2004. Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 stimulates the transcriptional activity of cellular IRF-3 and IRF-7. J. Biol. Chem. 279:7643-7654.
80. Lund, J., A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki. 2003. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198:513-520.
81. Marié, I., J. E. Durbin, and D. E. Levy. 1998. Differential viral induction of distinct interferon-α genes by positive feedback through interferon regulatory factor-7. EMBO J. 17:6660-6669.
82. Marié, I., E. Smith, A. Prakash, and D. E. Levy. 2000. Phosphorylationinduced dimerization of interferon regulatory factor 7 unmasks DNA binding and a bipartite transactivation domain. Mol. Cell. Biol. 20:8803-8814.
83. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521-530.
84. Means, R. E., S. M. Lang, and J. U. Jung. 2007. Human gammaherpesvirus immune evasion strategies, p. 559-586. In A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley, and K. Yamanishi (ed.), Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge, United Kingdom.
85. Medzhitov, R., et al. 1998. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2:253-258.
86. Mettenleiter, T. C., B. G. Klupp, and H. Granzow. 2009. Herpesvirus assembly: an update. Virus Res. 143:222-234.
87. Miller, G., et al. 1997. Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells. J. Virol. 71:314-324.
88. Moore, P. S., and Y. Chang. 1995. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N. Engl. J. Med. 332:1181-1185.
89. Moore, P. S., et al. 1996. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70:549-558.
90. Moore, P. S., C. Boshoff, R. A. Weiss, and Y. Chang. 1996. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274:1739-1744.
91. Moore, P. S., and Y. Chang. 2003. Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu. Rev. Microbiol. 57:609-639.
92. Mossman, K. L., et al. 2001. Herpes simplex virus triggers and then disarms a host antiviral response. J. Virol. 75:750-758.
93. Naranatt, P. P., et al. 2004. Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res. 64:72-84.
94. Paulose-Murphy, M., et al. 2001. Transcription program of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J. Virol. 75:4843-4853.
95. Perry, S. T., and T. Compton. 2006. Kaposi's sarcoma-associated herpesvirus virions inhibit interferon responses induced by envelope glycoprotein gpK8.1. J. Virol. 80:11105-11114.
96. Platanias, L. C. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5:375-386.
97. Pozharskaya, V. P., et al. 2004. Short duration of vIRF-1 expression during lytic replication of human herpesvirus 8 limits its ability to block antiviral responses induced by alpha interferon in BCBL-1 cells. J. Virol. 78:6621-6635.
98. Qin, B. Y., et al. 2003. Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat. Struct. Biol. 10: 913.
99. Rehli, M., et al. 2000. PU. 1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J. Biol. Chem. 275:9773-9781.
100. Renne, R., et al. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2:342-346.
101. Rezaee, S. A. R., C. Cunningham, A. J. Davison, and D. J. Blackbourn. 2006. Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J. Gen. Virol. 87:1781-1804.
102. Rivas, C., A.-E. Thlick, C. Parravicini, P. S. Moore, and Y. Chang. 2001. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75:429-438.
103. Russo, J. J., et al. 1996. Nucleotide sequence of the Kaposi sarcomaassociated herpesvirus (HHV8). Proc. Natl. Acad. Sci. U. S. A. 93:14862-14867.
104. Sadler, A. J., and B. R. G. Williams. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568.
105. Safai, B. 1984. Kaposi's sarcoma: a review of the classical and epidemic forms. Ann. N. Y. Acad. Sci. 437:373-382.
106. Sangfelt, and H. Strander. 2001. Apoptosis and cell growth inhibition as antitumor effector functions of interferons. Med. Oncol. 18:3-14.
107. Sarid, R., O. Flore, R. A. Bohenzky, Y. Chang, and P. S. Moore. 1998. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J. Virol. 72:1005-1012.
108. Sasai, M., et al. 2005. Cutting edge: NF-κB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation. J. Immunol. 174:27.
109. Sathish, N., F. X. Zhu, E. E. Golub, Q. Liang, and Y. Yuan. 2011. Mechanisms of autoinhibition of IRF-7 and a probable model for inactivation of IRF-7 by Kaposi's sarcoma-associated herpesvirus protein ORF45. J. Biol. Chem. 286:746-756.
110. Sato, M., et al. 1998. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441:106-110.
111. Sato, M., et al. 2000. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-α/β gene induction. Immunity 13:539-548.
112. Sato, S., et al. 2003. Toll/IL-1 receptor domain-containing adaptor inducing IFN-β (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J. Immunol. 171:4304-4310.
113. Schwam, D. R., R. L. Luciano, S. S. Mahajan, L. Wong, and A. C. Wilson. 2000. Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. J. Virol. 74:8532-8540.
114. Servant, M. J., B. Tenoever, and R. Lin. 2002. Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function. J. Interferon Cytokine Res. 22:49-58.
115. Sharma, S., B. R. tenOever, N. Grandvaux, G. P. Zhou, R. Lin, and J. Hiscott. 2003. Triggering the interferon antiviral response through an IKKrelated pathway. Science 300:1148-1151.
116. Sharma-Walia, N., et al. 2005. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J. Virol. 79:10308-10329.
117. Soulier, J., et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86:1276-1280.
118. Sun, R., et al. 1998. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc. Natl. Acad. Sci. U. S. A. 95:10866-10871.
119. Sun, R., et al. 1999. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J. Virol. 73:2232-2242.
120. Takaoka, A., S. Hayakawa, H. Yanai, D. Stoiber, H. Negishi, et al. 2003. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defense. Nature 424:516-523.
121. Takaoka, A., T. Tamura, and T. Taniguchi. 2008. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci. 99:467-478.
122. Takeda, K., and S. Akira. 2005. Toll-like receptors in innate immunity. Int. Immunol. 17:1-14.
123. Taniguchi, T., and A. Takaoka. 2001. A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2:378-386.
124. Thomas, M., et al. 2008. Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 105:1656-1661.
125. Verma, S. C., K. Lan, and E. Robertson. 2007. Structure and function of latency-associated nuclear antigen. Curr. Top. Microbiol. Immunol. 312: 101-136.
126. Wang, C. Y., and B. Sugden. 2004. New viruses shake old paradigms. J. Clin. Invest. 113:21-23.
127. Wang, F. Z., S. M. Akula, N. O. Pramod, L. Zeng, and B. Chandran. 2001. Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate. J. Virol. 75:7517-7527.
128. West, J., and B. Damania. 2008. Upregulation of the TLR3 pathway by Kaposi's sarcoma-associated herpesvirus during primary infection. J. Virol. 82:5440-5449.
129. Wies, E., et al. 2009. The Kaposi's sarcoma-associated herpesvirus-encoded vIRF-3 inhibits cellular IRF-5. J. Biol. Chem. 284:8525-8538.
130. Yamamoto, M., et al. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol. 169:6668-6672.
131. Yamamoto, M., et al. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640-643.
132. Yoneyama, M., et al. 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17:1087.
133. Yu, Y., S. E. Wang, and G. S. Hayward. 2005. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22:59-70.
134. Zhang, L., and J. S. Pagano. 2002. Structure and function of IRF-7. J. Interferon Cytokine Res. 22:95-101.
135. Zhong, W., H. Wang, B. Herndier, and D. Ganem. 1996. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc. Natl. Acad. Sci. U. S. A. 93:6641-6646.
136. Zhou, F. C., et al. 2002. Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J. Virol. 76:6185-6196.
137. Zhu, F. X., T. Cusano, and Y. Yuan. 1999. Identification of the immediateearly transcripts of Kaposi's sarcoma-associated herpesvirus. J. Virol. 73: 5556-5567.
138. Zhu, F. X., S. M. King, E. J. Smith, D. E. Levy, and Y. Yuan. 2002. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc. Natl. Acad. Sci. U. S. A. 99:5573-5578.
139. Zhu, F. X., and Y. Yuan. 2003. The ORF45 protein of Kaposi's sarcomaassociated herpesvirus is associated with purified virions. J. Virol. 77:4221-4230.
140. Zhu, F. X., J. M. Chong, L. Wu, and Y. Yuan. 2005. Virion proteins of Kaposi's sarcoma-associated herpesvirus. J. Virol. 79:800-811.
141. Zhu, F. X., X. Li, F. Zhou, S. J. Gao, and Y. Yuan. 2006. Functional characterization of Kaposi's sarcoma-associated herpesvirus ORF45 by bacterial artificial chromosome-based mutagenesis. J. Virol. 80:12187-12196.
142. Zhu, F. X., N. Sathish, and Y. Yuan. 2010. Antagonism of host antiviral responses by Kaposi's sarcoma-associated herpesvirus tegument protein ORF45. PLoS One 5:e10573.
143. Zimring, J. C., S. Goodbourn, and M. K. Offermann. 1998. Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J. Virol. 72:701-707.